Abstract
Background
Sarcomas are rare tumors of mesenchymal origin, accounting for nearly 21 and <1% of all pediatric and adult solid malignant tumors, respectively [1] .
Clinical trial research in disease with a low incidence like sarcomas (<6 per 100,000 people per year) is crucial to guarantee to the affected population the opportunity to access new treatments and benefit from medical and scientific progresses [2, 3] . However, in rare diseases, clinical research is challenging: few clinical trials are available for these populations and patients encounter difficulties in accessing
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In addition, conventional clinical trial designs are not always applicable and the statistical design needs to be modulated in order to make the studies feasible also in small populations [5] [6] [7] [8] [9] .
The management of sarcomas poses several problems and the need for reference centers to share their experiences let to the creation of networks and consortia of specialists [10, 11] .
From the late eighties the Italian reference centers specialized in sarcoma treatment, began to collaborate within some national research programs and participated to the development of investigator-initiated clinical trials [12, 13] .
From this experience, they felt the need to share their expertise and joint together in an Italian research network aimed to improve the academic research and committed to try to provide answers to unmet clinical questions, especially in the extremely rare sarcomas, or for peculiar sarcoma subtypes.
Thus in 1997, the Italian Sarcoma Group (ISG) was founded and, legally recognized as a scientific independent non-profit association in 2002, begun to promote independent clinical trials.
From the time the European Clinical Trials Directive 2001/20/CE [14] was fully adopted in Italy, at the end of 2007, its effects resulted in an increased in strictness and complexity of trial activities and trial oversight procedures.
This regulation, the chance to increase the number of trials conducted within international consortia [15, 16] and a greater interest of pharmaceutical companies in supporting independent research, imposed the need to introduce in the ISG organization, a Clinical Trial Unit (CTU) exclusively dedicated to Clinical Trial Operations to serve as an operative focal point for national and collaborative trials in sarcomas.
Methods

Development of the Clinical Trial Unit
The proposal to implement a CTU was presented to the ISG Directive Executive Board in 2009 that granted its approval for the initial financial support.
The source of funds was covered by the fundraising activities of the group and by the internal overheads derived from previous supported studies The main CTU office was established at central level and, under the central coordination, two satellites offices were introduced in other institutions.
The assigned mission to CTU was to promote high quality standard of the group promoted research, to guarantee the compliance with regulation, to provide central support to participating sites, to facilitate collaboration between them and to collaborate with the other European sarcoma cooperative groups, involved in common international studies.
Analysis
The impact of the CTU in ISG clinical research was assessed by comparing the number of clinical studies, the number of activated sites and of enrolled patients, the performance in data collection and the funds received to conduct the trials, in the time period from 2010 to the 3rd quarter of 2016.
The analysis included data of interventional, translational and observational studies as well as the educational activity promoted by the CTU.
Results
The first step toward the CTU creation was to implement the Clinical Operation (ClinOp) services, within the ISG secretariat by part-time personnel with a previous specific expertise in the management of clinical trials in sarcomas.
Among the first services offered were those related to study monitoring (site initiation, monitoring, and closeout visits) and to the development of specific Clinical Trial Monitoring Standard Operative Procedures, (CTMSOPs) to be applied to all the ISG clinical trials, in full compliance with the regulatory requirements.
From 2010 to 2012 the number of interventional clinical trials and centers completely managed by ISG ClinOp, increased respectively of 75% (from 4 to 7 studies) and 158% (from 26 to 67 activated sites).
As consequence to these first positive results an internal budget analysis was performed.
The recorded increase of funds (+48%) allowed ISG to introduce a fully independent CTU, able to cover its own expenses with their services.
CTU was then formally recognized by ISG and, from mid-2013, the ISG ClinOp were no longer part of the secretariat services, but started to be delivered by the independent CTU.
Responsibility of the CTU is to oversight the trial management for interventional and observational multi-sites clinical studies where ISG is sponsor or national coordinator within international consortia networks programs.
As reporte d in Table 1 , the services offered by CTU to the group are focused on 5 main domains: scientific support, project management, safety and regulatory management, educational and CTU administrative management.
From the beginning of 2014 the CTU also introduced an independent pharmacovigilance office and developed Standard Operative Procedures (SOP) to cover all the safety related activities.
When the first ISG ClinOp services were implemented in 2010, 6 studies (4 interventional and 2 observational) were ongoing and were mainly managed by the coordinating investigators.
The trials promoted by ISG or in collaboration with other international sarcoma networks in mid-2016 were 25: 17 (68%) interventional and 8 (32%) observational (Table 2) . 52% (n = 9) of the interventional have financial support from pharmaceutical companies, while 24% (n = 4) received funds within sarcoma European Commission projects and 24% (n = 4) are supported by ISG itself (Table 3) . Taking into account only the interventional studies, whereof regulatory requirements impose stringent quality standards, a great improvement in the number of managed clinical sites and patients has been 
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Study feasibility
Support to sites selection through site feasibility development within the study board recorded from 2010 to mid-2016, bringing the CTU to manage from 25 to 119 sites (+376%) and more than 800 active patients (+543%) with an mean increase, respectively, of 31 and 38% per year (Table 4) . Also a speed up in the time of ethical approval and in first patient enrollment have been recorded: a reduced mean time for approval of 4 months (and of 2 months for the First Patient First Visit).
During its 6 years of activity the high quality standard of clinical trial management, together with the capability of providing a comprehensive service for the ClinOp, brought the Italian Sarcoma Group to increase its collaborations within international cooperative groups (from 0 to 9 cooperative studies).
The services offered by the CTU had also impact on the supported research activity, with a more than sevenfold increase of funds from 2010 to 2016, and a mean number of new contracts for supported trials, in the last 3 years, of 3.3 (Table 5) .
On the other hand, the increase of research management activities brought the need to potentiate the CTU personnel that, in mid-2016 account for 2 full time units and 5 partially dedicated units from satellites.
The key effort of the CTU in facilitating the collaboration within consortia trials led ISG to join as partner or leader in several European consortia studies.
This also permitted a direct collaborations with other European sarcoma CTU through the sharing of SOP and of the best ClinOp practices.
All the results of the ISG clinical studies, oversight by the CTU, are object of international meeting presentations and are published in the most important peer reviewed oncology journals.
The CTU is also committed in promoting educational and training activities, like periodic courses, addressed not only to Clinical Research Coordinators (CRC) and to the Investigators interested in clinical trial regulation and research methodology. As part of the educational mission of the CTU, from 2013 ISG introduced in its annual meeting, a parallel section dedicated to clinical trial coordination where regulatory and breaking news from trial regulation and methodology are presented.
The personnel of the CTU also collaborate with national groups in research methodology education and is involved in research in the field of clinical trial regulations [17, 18] .
Discussion
In the last decade, ISG research network played a key role in the development of independent research in the sarcoma field, in Italy, promoting more than 30 clinical trials and managing over 100 sites with more than 800 patients. The number of clinical trials increased steadily from the CTU introduction, and the possibility to independently manage them, contributed to increase the number of consortia and pharmaceutical supported research. This led to a significant annual income increase that resulted in a self-financing system where the CTU is able to provide to its own maintenance.
Reduced time for regulatory approvals, immediate and continuous support to sites, and speed up in data collection and analysis, are making the ISG clinical research attractive for pharmaceutical industries, despite the fact that independent research in this field has been extremely challenging in the last years.
Finally, the feedback received from the ISG investigators about the support provided by CTU is extremely positive and contributes to increase the network collaboration and involvement, not only in terms of recruitment and data quality, but also in terms of clinical trial coordination activities.
Conclusion
Contribution of ISG researchers to the international community was considered from the earliest years of ISG creation.
The regulatory trial scenario requires a more solid and hard-fast methodology with depth knowledge and expertise. These challenges highlighted the need to identify expert and dedica ted professionals able to run, manage and follow the multifaceted aspects of innovative clinical trials.
The proactive collaboration between clinicians and CTU professionals made possible to support the increasing research activity with high scientific and ethical standards.
The introduction of the CTU within the ISG organization represented an important a chievement in the group's research activity, by facilitating its conduction.
This allows the group to be competitive and be recognized as a reliable partner within the international sarcoma networks and to lead the conduction of consortia clinical trials. 
